ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. ABL combines its expertise in translational science together with operational excellence to solve the challenging product development problems that are often faced by their clients as they bring their life-changing technologies to the world.
With cGMP facilities located in the U.S. and Europe, ABL is well positioned to provide comprehensive development and manufacturing support for protein and virus production utilizing single-use bioreactor platforms and other disposable technologies. ABL provides their clients with a fully integrated solution that includes cell line and process development, GMP manufacturing, QC release testing and QA/Regulatory support.
ABL’s contract research teams have decades of experience with immunoassays, developing custom assays and panels to support human clinical trials and preclinical animal studies. They routinely work with clients to design and run immunogenicity studies, biomarker analyses and other evaluations to better understand the impact of cutting-edge therapies: the mechanism of action, correlates of protection, pharmacokinetic/pharmacodynamics studies and other critical safety and efficacy data.
ABL is a subsidiary of the Institut Mérieux, a global organization committed to serving medicine and public health across the globe.
ABL’s mission is to provide integrated product development services at the highest quality to advance client products from target discovery to IND.